Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 5/20 | 0.46 |
| ▸ | NPC1 | O15118 | 4/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 9/20 | 0.41 |
| ▸ | CA2 | P00918 | 9/20 | 0.41 |
| ▸ | CA4 | P22748 | 9/20 | 0.41 |
| ▸ | CA9 | Q16790 | 9/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18281724 | 0.81 | RAB9A (0.57) | RAB9ANPC1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL3494366 | 0.75 | TEAD1 (0.50) | RAB9ANPC1KMT2ASMN1; SMN2 | |
| SCHEMBL4282201 | 0.75 | MAN1B1 (0.38) | RAB9ANPC1SMN1; SMN2CA1CA2 | |
| SCHEMBL4281174 | 0.75 | ALDH1A1 (0.46) | RAB9ANPC1KMT2APOLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL4285449 | 0.74 | KMT2A (0.57) | RAB9ANPC1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL4284550 | 0.74 | TEAD1 (0.46) | RAB9ANPC1KMT2APOLBSMN1; SMN2 | |
| SCHEMBL13705284 | 0.73 | PARP1 (0.56) | RAB9ANPC1SMN1; SMN2 | |
| SCHEMBL4297127 | 0.73 | CA1 (0.36) | KMT2ACA1CA2CA4CA9 | |
| SCHEMBL4291047 | 0.73 | TACR1 (0.43) | KMT2A | |
| SCHEMBL4788402 | 0.72 | CA1 (0.35) | CA1CA2CA4CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227560-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-10 | — | — | US | disclosed |
| US-20090156612-A1 | Substituted imidazole compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-06-18 | — | — | US | disclosed |
| WO-2008139941-A1 | SUBSTITUTED IMIDAZOLE COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156612-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | RAB9A 1247/4885NPC1 1165/4885KMT2A 1049/4885 |
| US-20090227560-A1 | Substituted imidazole compound and use thereof | REN, ACE, AGT | RAB9A 1247/4885NPC1 1165/4885KMT2A 1049/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.